<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00451763</url>
  </required_header>
  <id_info>
    <org_study_id>165/07</org_study_id>
    <nct_id>NCT00451763</nct_id>
  </id_info>
  <brief_title>Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia</brief_title>
  <official_title>Intravitreal Bevacizumab for Idiopathic Macular Telangiectasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Idiopathic Macular Telangiectasia is characterized by incompetent and dilated retinal
      capillaries in the foveolar region of unknown cause for retinal telangiectasia.

      In Idiopathic Macular Telangiectasia, proliferative changes occur in the deep retinal
      capillary network, leading to intraretinal neovascularization that, unlike in age-related
      macular degeneration, seems to be retinal rather than choroidal in origin. Before the
      hemorrhagic and fibrotic state, these vessels may lead to exudation and decrease in the
      visual acuity. Long-term visual prognosis in patients with this complication may be poor and
      treatment with laser photocoagulation is unproven. Although newly reported treatment, by
      photodynamic therapy for neovascular membrane associated with Idiopathic Macular
      Telangiectasia, may show vision and angiographic stability in a few cases, the improvement
      may be transient. VEGF has been implicated as the major angiogenic stimulus responsible for
      neovascularization in AMD, ensuing specific anti-VEGF treatment in these cases.

      The purpose of the study is to evaluate intravitreal injection of bevacizumab (1.25mg/0.05ml)
      in the treatment of Idiopathic Macular Telangiectasia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Optical coherence tomography</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein angiography</measure>
  </primary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Retina</condition>
  <condition>Telangiectasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with idiopathic macular telangiectasia

          -  patient consent

        Exclusion Criteria:

          -  heart attack or cerebrovascular attack

          -  previous treatment for others retinopathy

          -  media opacities that preclude visualization of the fundus

          -  inability to understands the implications of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Y Takahashi, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of São Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Otacilio O Maia Jr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sao Rafael Hospital, Monte Tabor Foudation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>From the Retina and Vitreous Service, Department of Ophthalmology. Sao Rafael Hospital, Monte Tabor Foudation</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41253-190</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2007</study_first_submitted>
  <study_first_submitted_qc>March 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2007</study_first_posted>
  <last_update_submitted>July 21, 2008</last_update_submitted>
  <last_update_submitted_qc>July 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2008</last_update_posted>
  <keyword>Fovea centralis/pathology</keyword>
  <keyword>Fundus oculi</keyword>
  <keyword>Retinal neovascularization</keyword>
  <keyword>Telangiectasis/diagnosis</keyword>
  <keyword>Tomography, optical coherence</keyword>
  <keyword>Vitreous Body/drug effects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telangiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

